AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL

Other

Brand names: amlodipine besylate and olmesartan medoxomil

Oral

Mechanism of Action

12.1 Mechanism of Action Amlodipine besylate and olmesartan medoxomil is a combination of two antihypertensive drugs: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, olmesartan medoxomil. The amlodipine component of amlodipine besylate and olmesartan medoxomil inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, and the olmesartan medoxomil component of amlodipine besylate and olmesartan medoxomil blocks the vasoconstrictor effects of angiotensin II. Amlodipine . Experimental data suggests that amlodipine binds to both dihydropyridine and nonhydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect o

Indications

1 INDICATIONS AND USAGE Amlodipine besylate and olmesartan medoxomil is indicated for the treatment of hypertension

alone or with other antihypertensive agents

to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events

including

as appropriate

lipid control

FDA Warnings

5 WARNINGS AND PRECAUTIONS Anticipate hypotension in volume- or salt-depleted patients with treatment initiation
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death
, patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria or progressive azotemia and (rarely) with acute renal failure and/or death

Known Side Effects

12 documented side effects by frequency

Fatigue

1-10%

Diarrhea

1-10%

Nausea

1-10%

Shortness of Breath

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Headache

1-10%

Weakness

1-10%

Falls

1-10%

Vomiting

1-10%

High Blood Pressure

1-10%

General Unwellness

1-10%

Community Discussions

No community discussions found for AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral